drug development

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
BioSpace
cancer
R&D
drug development
Boehringer Ingelheim
Epizyme
Flag link:
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
EP Vantage
Eli Lilly
drug development
Alzheimer's disease
BACE inhibitors
Flag link:
Billions Will Be Poured Into AI Drug Development
Billions Will Be Poured Into AI Drug Development
Forbes
artificial intelligence
drug development
Flag link:
AI Doesn't Ask Why -- But Physicians And Drug Developers Want To Know
AI Doesn't Ask Why -- But Physicians And Drug Developers Want To Know
Forbes
artificial intelligence
drug development
physicians
Flag link:
Novartis Plans for 60 Regulatory Filings Over the Next Three Years
Novartis Plans for 60 Regulatory Filings Over the Next Three Years
BioSpace
Novartis
drug development
R&D
Flag link:
Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs
Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs
Xconomy
Eli Lilly
NextCure
cancer immunotherapy
drug development
Flag link:
New prize offers $2 million for finding key to Alzheimer’s in past research
New prize offers $2 million for finding key to Alzheimer’s in past research
Stat
Alzheimer's disease
R&D
drug development
Flag link:
GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage
GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage
Endpoints
GSK
R&D
drug development
clinical trials
Flag link:
Novartis Cuts 20% of Drug-Research Projects After Review
Novartis Cuts 20% of Drug-Research Projects After Review
Bloomberg
Novartis
R&D
drug development
Flag link:
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets
Fierce Biotech
Pfizer
Novartis
NASH
drug development
Flag link:
How A Small Scottish Biotech Firm Could Win A Decisive Battle Against Cancer
How A Small Scottish Biotech Firm Could Win A Decisive Battle Against Cancer
Forbes
Nucana
Scotland
cancer
drug development
Flag link:
FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets
FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets
Endpoints
FDA
generics
drug development
Flag link:
Pharma Failures Actually Advance Medicine
Pharma Failures Actually Advance Medicine
Forbes
FDA
R&D
drug development
Pfizer
Torcetrapib
Flag link:
GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round
GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round
Fierce Biotech
GSK
Sitryx
immunometabolism
drug development
drug discovery
Flag link:
Evotec and Sanofi Join to Further Cutting-Edge Therapeutic Drug Discovery
Evotec and Sanofi Join to Further Cutting-Edge Therapeutic Drug Discovery
BioSpace
Sanofi
Evotex
drug development
LAB031
Flag link:
Are drug R&D costs exaggerated for effect? Researchers peg the median price of pivotal success at an economical $19M
Are drug R&D costs exaggerated for effect? Researchers peg the median price of pivotal success at an economical $19M
Endpoints
R&D
drug development
FDA
Flag link:
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
CP Wire
Roche
Go Therapeutics
drug development
bispecific antibodies
Flag link:
Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects
Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects
Endpoints
Loyola University
CAR-T
drug development
Flag link:
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
BioCentury
Ionis Pharmaceuticals
Rockefeller University
Alzheimer's disease
drug development
Flag link:
Why Corbus Pharmaceuticals Holdings Inc. Tumbled Today
Why Corbus Pharmaceuticals Holdings Inc. Tumbled Today
Motley Fool
Corbus Pharmaceuticals
cannabindoids
drug development
Flag link:

Pages